Procept Biorobotics Corporation  (PRCT)
Other Ticker:  
Price: $50.7500 $1.91 3.911%
Day's High: $51.005 Week Perf: 4.57 %
Day's Low: $ 48.68 30 Day Perf: 9.97 %
Volume (M): 805 52 Wk High: $ 51.90
Volume (M$): $ 40,854 52 Wk Avg: $35.62
Open: $49.48 52 Wk Low: $24.83

 Market Capitalization (Millions $) 2,452
 Shares Outstanding (Millions) 48
 Employees -
 Revenues (TTM) (Millions $) 116
 Net Income (TTM) (Millions $) -107
 Cash Flow (TTM) (Millions $) 38
 Capital Exp. (TTM) (Millions $) 17

Procept Biorobotics Corporation
Procept Biorobotics Corporation is a medical technology company that focuses on developing innovative medical devices to improve patient outcomes. The company primarily specializes in creating surgical robots and robotic systems for urological procedures. Procept Biorobotics' flagship product is the AquaBeam' Robotic System, which utilizes waterjet technology to remove tissue during surgery. The company's mission is to provide minimally invasive surgical solutions that enhance precision, decrease complications, and optimize patient recovery. Procept Biorobotics aims to revolutionize the field of urology by offering advanced robotic technologies that allow for more efficient and effective procedures.

   Company Address: 150 Baytech Drive San Jose 95134 CA
   Company Phone Number: 232-7200   Stock Exchange / Ticker: NASDAQ PRCT


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Procept Biorobotics Corporation

Procept Biorobotics Corporation's Remarkable Surge: Impressive Growth amidst Fiscal Third Quarter of 2023

Procept Biorobotics Corporation (Procept) is an innovative medical technology company that specializes in the development and commercialization of robotic surgical systems. The company's goal is to revolutionize the field of urology by providing surgeons with advanced tools to more effectively and efficiently perform minimally invasive procedures.
In the financial third quarter of 2023, Procept reported a loss of $0.51 per share, which was the same as the previous year. However, there was an improvement in earnings per share (EPS) from the prior reporting season, increasing from $0.56 per share. Despite the loss, the company experienced strong revenue growth of 71.379%, reaching $34.87 million compared to the $20.35 million reported in the same period a year ago. Sequentially, revenue also grew by 5.347% compared to the previous quarter's $33.10 million.

Procept Biorobotics Corporation

Procept Biorobotics Corporation Reports a Significant Increase in Revenue Despite Larger Losses in Q2 2023; Outperforms Medical Equipment Industry Trend

Financial News Report:
Procept Biorobotics Corporation Posts Widened Losses but Strong Revenue Growth in Q2 2023
Procept Biorobotics Corporation (PRCT), a leading player in the Medical Equipment & Supplies industry, reported its financial results for the second quarter of 2023. The company witnessed a widening of losses compared to the same period last year, but also saw improvements in its income per share. However, the standout achievement was the significant growth in revenue, which far exceeded industry trends.
In terms of earnings per share (EPS), PRCT reported a loss of $-0.56, compared to a loss of $-0.43 in the same quarter of the previous year. However, the company's income per share showed improvement, increasing from $-0.63 in the prior reporting season.

Procept Biorobotics Corporation

Medical Equipment & Supplies Company's Impressive Growth and Resilience in Q1 2023 Earnings Season

Procept Biorobotics Corporation, despite recording a deficit per share of $-0.63 per share for the first quarter of 2023 earnings season, has shown great resilience and potential in terms of revenue growth. The company's revenue soared by a whopping 71.895% to $24.40 million, compared to $14.20 million in the same quarter of the previous year. It is important to note that sequentially, the revenue also increased by 2.637% from $23.78 million in the previous quarter. This indicates that the company has been able to make significant strides in terms of revenue growth.
It is noteworthy that even though there is an increase in deficit per share, Procept Biorobotics Corporation realized a net deficit of $-28.484 million for the first quarter of 2023, which is higher than the $-17.185 million of the previous year. This is not necessarily a sign of poor performance, as the company was able to increase its revenue significantly. Therefore, it can be assumed that the company is investing heavily in research and development, which will enable it to generate greater revenues in the future.


Procept Biorobotics's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com